Ornithine Aketoglutarate

Ornithine Aketoglutarate

SCHEMBL16097781

CC(O)CC(=O)O.NCCCC(N)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSR P00390 2/20 0.60
▸ BHMT Q93088 1/20 0.47
▸ CYP1A2 P05177 3/20 0.44
▸ GRM8 O00222 1/20 0.44
▸ GRM6 O15303 1/20 0.44
▸ GRIN2D O15399 1/20 0.44
▸ GRIN3B O60391 1/20 0.44
▸ GRIK1 P39086 1/20 0.44
▸ GRM5 P41594 1/20 0.44
▸ GRIA1 P42261 1/20 0.44
▸ GRIA2 P42262 1/20 0.44
▸ GRIA3 P42263 1/20 0.44
▸ SLC1A3 P43003 1/20 0.44
▸ SLC1A2 P43004 1/20 0.44
▸ SLC1A1 P43005 1/20 0.44
▸ GRIA4 P48058 1/20 0.44
▸ GRIN1 Q05586 1/20 0.44
▸ GRIN2A Q12879 1/20 0.44
▸ GRIK2 Q13002 1/20 0.44
▸ GRIK3 Q13003 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ornithine SCHEMBL16097782 1.00 GSR (0.60) GSRBHMTCYP1A2GRM8GRM6
Lysine SCHEMBL16099031 0.95 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Lysine SCHEMBL16099029 0.95 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Aspartic Acid SCHEMBL27955723 0.85 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Aspartic Acid SCHEMBL8919110 0.85 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Aspartic Acid SCHEMBL28321586 0.85 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Ornithine SCHEMBL361185 0.85 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Ornithine Aketoglutarate SCHEMBL361184 0.85 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Aspartic Acid SCHEMBL755884 0.85 GSR (0.69) GSRBHMTCYP1A2GRM8GRM6
Carnitine SCHEMBL28276640 0.85 SLC22A16 (0.51) GSRBHMTCYP1A2GRM8GRM6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11806328-B2 Metabolic therapy for wound healing UNIVERSITY OF SOUTH FLORIDA (US) 2023-11-07 — — US claimed
US-20210093602-A1 METABOLIC THERAPY FOR WOUND HEALING UNIVERSITY OF SOUTH FLORIDA 2021-04-01 — — US claimed
US-10864184-B1 Metabolic therapy for wound healing UNIVERSITY OF SOUTH FLORIDA (US) 2020-12-15 — — US claimed
US-20200268701-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIV SOUTH FLORIDA (US) 2020-08-27 — — US claimed
US-10646462-B2 Compositions and methods for producing elevated and sustained ketosis UNIVERSITY OF SOUTH FLORIDA (US) 2020-05-12 — — US claimed
CN-105050594-B For generating the composition and method that increase with lasting ketosis 南佛罗里达大学 2019-11-12 — — CN claimed
WO-2019200132-A1 COMPOSITIONS AND METHODS FOR SUPPLEMENTING THE DIET Metabolic Recovery Systems, LLC (US) 2019-10-17 — — WO claimed
EP-2976073-B1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIV SOUTH FLORIDA (US) 2019-08-28 — — EP claimed
CN-109394745-A A kind of composition comprising L-carnitine and beta-hydroxy-butanoic acid compound 博瑞生物医药(苏州)股份有限公司 2019-03-01 — — CN claimed
US-20180021281-A1 LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS SCIADONICS, INC. 2018-01-25 — — US claimed
WO-2018017667-A1 LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS SCIADONICS, INC. (US) 2018-01-25 — — WO claimed
US-20170266148-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2017-09-21 — — US claimed
US-9675577-B2 Compositions and methods for producing elevated and sustained ketosis UNIVERSITY OF SOUTH FLORIDA (US) 2017-06-13 — — US claimed
US-20160067207-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2016-03-10 — — US claimed
EP-2976073-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS University Of South Florida (US) 2016-01-27 — — EP claimed
CN-105050594-A Compositions and methods for producing elevated and sustained ketosis UNIV SOUTH FLORIDA 2015-11-11 — — CN claimed
US-20140350105-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2014-11-27 — — US claimed
WO-2014153416-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2014-09-25 — — WO claimed
US-20240226043-A1 ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANS AXCESS GLOBAL SCIENCES, LLC 2024-07-11 — — US disclosed
WO-2014153416-A1 COMPOSITIONS AND METHODS FOR PRODUCING ELEVATED AND SUSTAINED KETOSIS UNIVERSITY OF SOUTH FLORIDA (US) 2014-09-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180021281-A1 LIPID FORMULATIONS CONTAINING BIOACTIVE FATTY ACIDS AND OTHER BIOACTIVE AGENTS FAAH, ELOVL1, DGKA GSR 3037/4885BHMT 1320/4885CYP1A2 2832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback